Marwan Fakih, MD

Positioning fruquintinib and regorafenib against each other, and against trifluridine and tipiracil plus bevacizumab, increasingly comes down to individual tolerability, disease burden, and appropriate dose escalation strategy.

The SUNLIGHT trial redefined third-line expectations by pairing trifluridine and tipiracil with bevacizumab, while emerging every-other-week dosing data promise better tolerability without sacrificing efficacy.

Unresolved questions about immunotherapy duration, right-sided tumor biology, and earlier use of targeted agents illustrate how much remains unsettled in first- and second-line colorectal cancer management.

Early planning for third-line therapy, guided by subtle clinical and biochemical signals, now shapes how oncologists distinguish a true treatment rechallenge from a simple reintroduction of prior therapy.

Defining treatment failure depends on disease burden and biology, while circulating tumor DNA offers real but still limited practical value in guiding second-line therapy selection for metastatic colorectal cancer.

KEYNOTE-177 and CheckMate-8HW established immunotherapy as the frontline standard for MSI-high and deficient mismatch repair colorectal cancer, though managing the smaller subset of patients who progress remains genuinely complex.

Choosing between FOLFOX and FOLFIRI, and deciding when to shift to maintenance therapy, requires balancing prior treatment exposure, patient lifestyle, and the limited pool of active agents in colorectal cancer.

Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still varies across practice settings nationwide.

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.